Regeneron Reports 73% Response Rate for Ovarian Cancer Drug Trial

3-line summary

• Regeneron reported a 73% response rate for its ovarian cancer drug trial, according to an Investing.com report.

This summary is our own processing of the source article; see the source link below for full context.